GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gossamer Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.43−0.34 (-3.88%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Gossamer Bio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -311.7%
- Net margin
- -235.0%
- Return on equity, FY2025
- 365.3%
Financial strength
- Current ratio
- 0.53
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 29.9%
Valuation
- P/E ratio
- –
- Price to sales
- 52.01
- Price to book
- –
- Dividend yield
- –